Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients

Salah Aref1, Emad Azmy1, Kadry EL-Bakry2, Lobna Ibrahim2 and Mohamed Mabed1

1Mansoura University, Egypt
2Damietta University, Egypt

The aim of the study is to determine the prognostic relevance of CD200/CD56 expression in adult acute lymphoblastic leukemia patients. The expression of CD200 and CD56 by blast cells was assessed by flow cytometry before start of chemotherapy in 70 B-ALL patients. Positive expression of CD200 was detected in 46 patients (66%) and CD56 was detected in 7 patients (10%) out of 70 patients, respectively. Only 3 patient (4.3%) had co-expression for CD200+ and CD56+. Splenomegaly and thrombocytopenia were frequently observed more in CD200+ patients. Increased frequency of CD34+ was associated with CD200+ and CD56+ patients. The CD200+ and CD56+ subgroups of B-ALL patients had inferior OS and DFS compared to CD200− and CD56− patients. In conclusion, CD200+ and/or CD56+ positive expression in B-ALL patients at diagnosis is a poor prognostic biomarker. Identification of CD200+ and CD56+ expression at diagnosis is recommended for better stratification of adult B-ALL patients.

Biography

Salah Aref has completed his PhD from Mansoura University and Postdoctoral studies from Mansoura University, School of Medicine. He is the Director of Mansoutra University Oncology Center laboratories. He has published more than 60 papers in reputed journals and has been serving as an Editorial-Board Member of reputed journals. salaharef@yahoo.com

Notes: